Duncan P. Hennes
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
RenaissanceRe Q2 2026 Earnings Call Highlights Discounted Valuation. During the Q2 2026 earnings call, RenaissanceRe reiterated its diversified reinsurance strategy and maintained a cautious outlook. Analysts noted the stock trades at a discount to peers, with a 142% run and a P/E of 5.2, suggesting potential undervaluation. The company’s dividend yield of 0.69% and analyst target of $346.40 contrast with its current price near the 52‑week low of $231.17. RSI sits at 45.5 and the support level at $292.90 adds context to its valuation debate.
Transaction History
| C | ▲ Buy | Grant | 6 | $854 | 10/1/2026 | View on chart |
| C | ▲ Buy | Grant | 201 | $26K | 10/1/2026 | View on chart |
| C | ▲ Buy | Grant | 5 | $762 | 7/1/2026 | View on chart |
| C | ▲ Buy | Grant | 165 | $24K | 7/1/2026 | View on chart |
| C | ▲ Buy | Grant | 7 | $758 | 4/1/2026 | View on chart |
| C | ▲ Buy | Grant | 211 | $23K | 4/1/2026 | View on chart |
| RNR | ▲ Buy | Grant | 578 | $0 | 3/1/2026 | View on chart |
| C | ▲ Buy | Grant | 185 | $22K | 1/2/2026 | View on chart |
| C | ▲ Buy | Grant | 1,263 | $0 | 1/2/2026 | View on chart |
| C | ▲ Buy | Grant | 11 | $1K | 1/2/2026 | View on chart |
| C | ▲ Buy | Grant | 13 | $1K | 10/1/2025 | View on chart |
| C | ▲ Buy | Grant | 214 | $22K | 10/1/2025 | View on chart |
| C | ▲ Buy | Grant | 14 | $1K | 7/1/2025 | View on chart |
| C | ▲ Buy | Grant | 243 | $20K | 7/1/2025 | View on chart |
| C | ▲ Buy | Grant | 16 | $1K | 4/1/2025 | View on chart |
| C | ▲ Buy | Grant | 279 | $20K | 4/1/2025 | View on chart |
| RNR | ▲ Buy | Grant | 694 | $0 | 3/1/2025 | View on chart |
| C | ▲ Buy | Grant | 24 | $2K | 1/2/2025 | View on chart |
| C | ▲ Buy | Grant | 259 | $18K | 1/2/2025 | View on chart |
| C | ▲ Buy | Grant | 2,118 | $0 | 1/2/2025 | View on chart |
| C | ▲ Buy | Grant | 295 | $18K | 10/1/2024 | View on chart |
| C | ▲ Buy | Grant | 27 | $2K | 10/1/2024 | View on chart |
| C | ▲ Buy | Grant | 275 | $17K | 7/1/2024 | View on chart |
| C | ▲ Buy | Grant | 25 | $2K | 7/1/2024 | View on chart |
| C | ▲ Buy | Grant | 25 | $2K | 4/1/2024 | View on chart |
| C | ▲ Buy | Grant | 273 | $17K | 4/1/2024 | View on chart |
| RNR | ▲ Buy | Grant | 738 | $0 | 3/1/2024 | View on chart |
| C | ▲ Buy | Grant | 265 | $14K | 1/2/2024 | View on chart |
| C | ▲ Buy | Grant | 61 | $3K | 1/2/2024 | View on chart |
| C | ▲ Buy | Grant | 2,923 | $0 | 1/2/2024 | View on chart |
| C | ▲ Buy | Grant | 329 | $13K | 10/1/2023 | View on chart |
| C | ▲ Buy | Grant | 75 | $3K | 10/1/2023 | View on chart |
| C | ▲ Buy | Grant | 63 | $3K | 7/1/2023 | View on chart |
| C | ▲ Buy | Grant | 276 | $13K | 7/1/2023 | View on chart |
| C | ▲ Buy | Grant | 276 | $13K | 4/1/2023 | View on chart |
| C | ▲ Buy | Grant | 63 | $3K | 4/1/2023 | View on chart |
| RNR | ▲ Buy | Grant | 759 | $0 | 3/1/2023 | View on chart |
| C | ▲ Buy | Grant | 3,353 | $0 | 1/3/2023 | View on chart |
| C | ▲ Buy | Grant | 54 | $2K | 1/1/2023 | View on chart |
| C | ▲ Buy | Grant | 246 | $11K | 1/1/2023 | View on chart |
| C | ▲ Buy | Grant | 226 | $11K | 10/1/2022 | View on chart |
| C | ▲ Buy | Grant | 49 | $2K | 10/1/2022 | View on chart |
| C | ▲ Buy | Grant | 220 | $11K | 7/1/2022 | View on chart |
| C | ▲ Buy | Grant | 48 | $2K | 7/1/2022 | View on chart |
| C | ▲ Buy | Grant | 194 | $11K | 4/1/2022 | View on chart |
| C | ▲ Buy | Grant | 22 | $1K | 4/1/2022 | View on chart |
| RNR | ▲ Buy | Grant | 1,065 | $0 | 3/1/2022 | View on chart |
| C | ▲ Buy | Grant | 2,255 | $0 | 2/10/2022 | View on chart |
| C | ▲ Buy | Grant | 158 | $10K | 1/1/2022 | View on chart |
| C | ▲ Buy | Grant | 36 | $2K | 1/1/2022 | View on chart |
| C | ▲ Buy | Grant | 138 | $10K | 10/1/2021 | View on chart |
| C | ▲ Buy | Grant | 32 | $2K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
US presses China on Citigroup market access in Bangkok talks
The U.S. government has raised concerns about Citigroup's market access in China during bilateral talks in Bangkok. This diplomatic development highlights the ongoing regulatory and geopolitical risks associated with the bank's international operations. While Citi also initiated coverage on other companies like Mobileye, the trade discussions are the primary factor affecting the stock's broader outlook.
US presses China on Citigroup market access in Bangkok talks. The U.S. government has raised concerns about Citigroup's market access in China during bilateral talks in Bangkok. This diplomatic development highlights the ongoing regulatory and geopolitical risks associated with the bank's international operations. While Citi also initiated coverage on other companies like Mobileye, the trade discussions are the primary factor affecting the stock's broader outlook.